Show simple item record

dc.contributor.authorBosch, Jackie
dc.contributor.authorEikelboom, John W.
dc.contributor.authorConnolly, Stuart J.
dc.contributor.authorBruns, Nancy Cook
dc.contributor.authorLanius, Vivian
dc.contributor.authorYuan, Fei
dc.contributor.authorMisselwitz, Frank
dc.contributor.authorChen, Edmond
dc.contributor.authorDiaz, Rafael
dc.contributor.authorAlings, Marco
dc.contributor.authorLonn, Eva M.
dc.contributor.authorWidimsky, Petr
dc.contributor.authorHori, Masatsugu
dc.contributor.authorAvezum, Alvaro
dc.contributor.authorPiegas, Leopoldo S.
dc.contributor.authorBhatt, Deepak L.
dc.contributor.authorBranch, Kelley R.H.
dc.contributor.authorProbstfield, Jeffrey L.
dc.contributor.authorLiang, Yan
dc.contributor.authorLiu, Lisheng
dc.contributor.authorZhu, Jun
dc.contributor.authorMaggioni, Aldo P.
dc.contributor.authorLopez-Jaramillo, Patricio
dc.contributor.authorO'Donnell, Martin
dc.contributor.authorFox, Keith A.A.
dc.contributor.authorKakkar, Ajay
dc.contributor.authorParkhomenko, Alexander N.
dc.contributor.authorErtl, Georg
dc.contributor.authorStörk, Stefan
dc.contributor.authorKeltai, Katalin
dc.contributor.authorKeltai, Matyas
dc.contributor.authorRyden, Lars
dc.contributor.authorDagenais, Gilles R.
dc.contributor.authorPogosova, Nana
dc.contributor.authorDans, Antonio L.
dc.contributor.authorLanas, Fernando
dc.contributor.authorCommerford, Patrick J.
dc.contributor.authorTorp-Pedersen, Christian
dc.contributor.authorGuzik, Tomasz J.
dc.contributor.authorVerhamme, Peter B.
dc.contributor.authorVinereanu, Dragos
dc.contributor.authorKim, Jae-Hyung
dc.contributor.authorHa, Jong-Won
dc.contributor.authorTonkin, Andrew M.
dc.contributor.authorVarigos, John D.
dc.contributor.authorLewis, Basil S.
dc.contributor.authorFelix, Camilo
dc.contributor.authorYusoff, Khalid
dc.contributor.authorSteg, Philippe Gabriel
dc.contributor.authorAboyans, Victor
dc.contributor.authorMetsarinne, Kaj P.
dc.contributor.authorAnand, Sonia S.
dc.contributor.authorHart, Robert G.
dc.contributor.authorLamy, Andre
dc.contributor.authorMoayyedi, Paul
dc.contributor.authorLeong, Darryl P.
dc.contributor.authorSharma, Mukul
dc.contributor.authorYusuf, Salim
dc.identifier.citationBosch, Jackie; Eikelboom, John W. Connolly, Stuart J.; Bruns, Nancy Cook; Lanius, Vivian; Yuan, Fei; Misselwitz, Frank; Chen, Edmond; Diaz, Rafael; Alings, Marco; Lonn, Eva M.; Widimsky, Petr; Hori, Masatsugu; Avezum, Alvaro; Piegas, Leopoldo S.; Bhatt, Deepak L.; Branch, Kelley R.H.; Probstfield, Jeffrey L.; Liang, Yan; Liu, Lisheng; Zhu, Jun; Maggioni, Aldo P.; Lopez-Jaramillo, Patricio; O'Donnell, Martin; Fox, Keith A.A.; Kakkar, Ajay; Parkhomenko, Alexander N.; Ertl, Georg; Störk, Stefan; Keltai, Katalin; Keltai, Matyas; Ryden, Lars; Dagenais, Gilles R.; Pogosova, Nana; Dans, Antonio L.; Lanas, Fernando; Commerford, Patrick J.; Torp-Pedersen, Christian; Guzik, Tomasz J.; Verhamme, Peter B.; Vinereanu, Dragos; Kim, Jae-Hyung; Ha, Jong-Won; Tonkin, Andrew M.; Varigos, John D.; Lewis, Basil S.; Felix, Camilo; Yusoff, Khalid; Steg, Philippe Gabriel; Aboyans, Victor; Metsarinne, Kaj P.; Anand, Sonia S.; Hart, Robert G.; Lamy, Andre; Moayyedi, Paul; Leong, Darryl P.; Sharma, Mukul; Yusuf, Salim (2017). Rationale, design and baseline characteristics of participants in the c ardiovascular o utco m es for p eople using a nticoagulation s trategie s (compass) trial. Canadian Journal of Cardiology 33 (8), 1027-1035
dc.description.abstractBackground: Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alone or in combination with aspirin might be more effective than aspirin alone for vascular prevention in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD). Rivaroxaban as well as aspirin increase upper gastrointestinal (GI) bleeding and this might be prevented by proton pump inhibitor therapy. Methods: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) is a double-blind superiority trial comparing rivaroxaban 2.5 mg twice daily combined with aspirin 100 mg once daily or rivaroxaban 5 mg twice daily vs aspirin 100 mg once daily for prevention of myocardial infarction, stroke, or cardiovascular death in patients with stable CAD or PAD. Patients not taking a proton pump inhibitor were also randomized, using a partial factorial design, to pantoprazole 40 mg once daily or placebo. The trial was designed to have at least 90% power to detect a 20% reduction in each of the rivaroxaban treatment arms compared with aspirin and to detect a 50% reduction in upper GI complications with pantoprazole compared with placebo. Results: Between February 2013 and May 2016, we recruited 27,395 participants from 602 centres in 33 countries; 17,598 participants were included in the pantoprazole vs placebo comparison. At baseline, the mean age was 68.2 years, 22.0% were female, 90.6% had CAD, and 27.3% had PAD. Conclusions: COMPASS will provide information on the efficacy and safety of rivaroxaban, alone or in combination with aspirin, in the long-term management of patients with stable CAD or PAD, and on the efficacy and safety of pantoprazole in preventing upper GI complications in patients receiving antithrombotic therapy.
dc.publisherElsevier BV
dc.relation.ispartofCanadian Journal of Cardiology
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.subjectperipheral arterial-disease
dc.subjectrandomized controlled-trial
dc.subjectprior myocardial-infarction
dc.subjectacute coronary syndromes
dc.subjectlong-term use
dc.subjectatherothrombotic events
dc.subjectvenous thromboembolism
dc.subjectantiplatelet therapy
dc.subjectsecondary prevention
dc.titleRationale, design and baseline characteristics of participants in the c ardiovascular o utco m es for p eople using a nticoagulation s trategie s (compass) trial

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland